Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease (DRAMMATIC Study)

Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease (DRAMMATIC Study)
Recruiting
17 years - 75 years
All
Phase N/A
162 participants needed
1 Location

Brief description of study

This study will examine whether adding the drug daratumumab/rHuPH20 to the usual maintenance treatment with lenalidomide after stem cell transplant help multiple myeloma patients survive longer. For patients who do not have minimum residual disease [MRD-negative], this study is also trying to determine if maintenance therapy should be stopped after 2 years.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Myeloma
  • Age: 17 years - 75 years
  • Gender: All

Male and Female, Age 18-75, diagnosis of symptomatic multiple myeloma

Updated on 04 Aug 2024. Study ID: 834515

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center